BioSpace News Archive

Aquedeon Medical, Inc., a Silicon Valley pioneering medical device company specializing in novel cardiothoracic solutions, is pleased to announce a significant milestone following receipt of FDA Investigational Device Exemption approval to conduct a staged pivotal clinical trial for its Duett Vascular Graft System in the United States.

Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins to advance precision neuromedicines, announced that it has raised $150 million in Series B funding.

Asensus Surgical, Inc. announced that First Towakai Hospital has entered into an agreement to lease and utilize a Senhance® Surgical System in their urology and gynecology centers and gastroenterology department.

Genentech, a member of the Roche Group, has been made aware of an inadvertent disclosure of the second interim analysis of the Phase III SKYSCRAPER-01 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq® versus Tecentriq alone as an initial treatment for people with PD-L1-high locally advanced or metastatic non-small cell lung cancer.

The second quarter of the year saw an improvement in EBIT compared with recent quarters, continued high gross margins, strong growth and an exclusive collaboration and distribution agreement with US-based Thermo Fisher Scientific.

Medivir AB, a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will present at the Erik Penser Bank Company Event on Thursday, August 24, 2023.

The heart teams at the Piedmont Heart Institute in Atlanta, Georgia, USA and the University of Virginia Health System in Charlottesville, VA, USA, successfully performed the first two implantations in the US of the Trisol Transcatheter Tricuspid Valve Replacement as part of a U.S. Food and Drug Administration approved Early Feasibility Study, led by Principal Investigator Isaac George, MD.

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization, announced a capacity update with the addition of three new Grade B cell therapy suites to its Longmont, CO facility.

ANI Pharmaceuticals, Inc. announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We” or “Our”), announced today its joint venture partner, GMP Biotechnology Limited’s wholly owned subsidiary – Sapu Bioscience, LLC (“Sapu”), together with with Cromos Pharma, LLC (“Cromos”), a US-based international contract research organization (“CRO”), to conduct Sapu’s registrational trial for OT-101 in Pancreatic Cancer.